Combined dexamethasone/CRH test in rats: hypothalamo-pituitary-adrenocortical system alterations in aging. 1996

M Hatzinger, and J M Reul, and R Landgraf, and F Holsboer, and I Neumann
Max Planck Institute of Psychiatry, Clinical Institute, Munich, Germany.

Alterations of the hypothalamo-pituitary-adrenocortical (HPA) system are well-known phenomena in human aging as well as under stressful conditions and in psychiatric disorders. Among the various neuroendocrine function tests developed so far, the combined dexamethasone (DEX)/corticotropin-releasing hormone (CRH) test, in which DEX-pretreated subjects receive a single dose of CRH, has proved to be the most sensitive measure of subtle changes in HPA system regulation. To further explore the mechanisms underlying these neuroendocrine abnormalities in an animal model, a combined DEX/CRH test was established in young male Wistar rats. Five days before the experiment, the jugular vein was catheterized under halothane anesthesia for subsequent drug infusion and blood sampling. DEX (30 micrograms/kg) administered at 12.00 h, during the diurnal trough, suppressed the diurnal increase in circulating corticotropin (ACTH) and corticosterone between 18.00 and 20.00 h, during the acrophase. Subsequent CRH (50 ng/kg) infused at 20.00 h provoked a minimal escape from DEX suppression, indicated by a slight increase in ACTH and corticosterone secretion. Therefore, the combination of 30 micrograms/kg DEX given at 12.00 h followed by pituitary-adrenal system stimulation with 50 ng/kg CRH at 20.00 h was defined as the standard DEX/CRH test procedure and was then used in young (3-6 months) and aged male Wistar rats (20-24 months). After DEX treatment, basal ACTH levels between 18.00 and 20.00 h were significantly higher in aged than in young rats (77.6 +/- 23.2 vs. 19.9 +/- 0.9 pg/ml; p < 0.01), indicating resistance of the HPA system to the suppressive effect of DEX. In addition, the ACTH response to subsequent CRH was significantly higher in aged than in young animals (area under the concentration time curve: 3,670 +/- 2,230 vs. 294 +/- 112; p < 0.05). Thus, the HPA system appeared to be profoundly dysregulated in aged male Wistar rats. The elevated basal ACTH levels reflect glucocorticoid nonsuppression, suggesting negative feedback impairment. This is further supported by the elevated ACTH response to a subsequent CRH challenge, which, in addition, may indicate changes in the endogenous synergistic mechanisms of CRH with other corticotropic factors, for instance vasopressin. In summary, the DEX/ CRH test revealed HPA system alterations in aging and can be applied in future studies to further explore the mechanisms underlying the neuroendocrine disturbances during (psycho) pathological states.

UI MeSH Term Description Entries
D007031 Hypothalamus Ventral part of the DIENCEPHALON extending from the region of the OPTIC CHIASM to the caudal border of the MAMMILLARY BODIES and forming the inferior and lateral walls of the THIRD VENTRICLE. Lamina Terminalis,Preoptico-Hypothalamic Area,Area, Preoptico-Hypothalamic,Areas, Preoptico-Hypothalamic,Preoptico Hypothalamic Area,Preoptico-Hypothalamic Areas
D008297 Male Males
D010902 Pituitary Gland A small, unpaired gland situated in the SELLA TURCICA. It is connected to the HYPOTHALAMUS by a short stalk which is called the INFUNDIBULUM. Hypophysis,Hypothalamus, Infundibular,Infundibular Stalk,Infundibular Stem,Infundibulum (Hypophysis),Infundibulum, Hypophyseal,Pituitary Stalk,Hypophyseal Infundibulum,Hypophyseal Stalk,Hypophysis Cerebri,Infundibulum,Cerebri, Hypophysis,Cerebrus, Hypophysis,Gland, Pituitary,Glands, Pituitary,Hypophyseal Stalks,Hypophyses,Hypophysis Cerebrus,Infundibular Hypothalamus,Infundibular Stalks,Infundibulums,Pituitary Glands,Pituitary Stalks,Stalk, Hypophyseal,Stalk, Infundibular,Stalks, Hypophyseal,Stalks, Infundibular
D003345 Corticosterone An adrenocortical steroid that has modest but significant activities as a mineralocorticoid and a glucocorticoid. (From Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p1437)
D003346 Corticotropin-Releasing Hormone A peptide of about 41 amino acids that stimulates the release of ADRENOCORTICOTROPIC HORMONE. CRH is synthesized by neurons in the PARAVENTRICULAR NUCLEUS of the HYPOTHALAMUS. After being released into the pituitary portal circulation, CRH stimulates the release of ACTH from the PITUITARY GLAND. CRH can also be synthesized in other tissues, such as PLACENTA; ADRENAL MEDULLA; and TESTIS. ACTH-Releasing Hormone,CRF-41,Corticotropin-Releasing Factor,Corticotropin-Releasing Hormone-41,ACTH-Releasing Factor,CRF (ACTH),Corticoliberin,Corticotropin-Releasing Factor-41,ACTH Releasing Factor,ACTH Releasing Hormone,Corticotropin Releasing Factor,Corticotropin Releasing Factor 41,Corticotropin Releasing Hormone,Corticotropin Releasing Hormone 41
D003907 Dexamethasone An anti-inflammatory 9-fluoro-glucocorticoid. Hexadecadrol,Decaject,Decaject-L.A.,Decameth,Decaspray,Dexasone,Dexpak,Hexadrol,Maxidex,Methylfluorprednisolone,Millicorten,Oradexon,Decaject L.A.
D000302 Adrenal Cortex The outer layer of the adrenal gland. It is derived from MESODERM and comprised of three zones (outer ZONA GLOMERULOSA, middle ZONA FASCICULATA, and inner ZONA RETICULARIS) with each producing various steroids preferentially, such as ALDOSTERONE; HYDROCORTISONE; DEHYDROEPIANDROSTERONE; and ANDROSTENEDIONE. Adrenal cortex function is regulated by pituitary ADRENOCORTICOTROPIN. Cortex, Adrenal
D000324 Adrenocorticotropic Hormone An anterior pituitary hormone that stimulates the ADRENAL CORTEX and its production of CORTICOSTEROIDS. ACTH is a 39-amino acid polypeptide of which the N-terminal 24-amino acid segment is identical in all species and contains the adrenocorticotrophic activity. Upon further tissue-specific processing, ACTH can yield ALPHA-MSH and corticotrophin-like intermediate lobe peptide (CLIP). ACTH,Adrenocorticotropin,Corticotropin,1-39 ACTH,ACTH (1-39),Adrenocorticotrophic Hormone,Corticotrophin,Corticotrophin (1-39),Corticotropin (1-39),Hormone, Adrenocorticotrophic,Hormone, Adrenocorticotropic
D000375 Aging The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time. Senescence,Aging, Biological,Biological Aging
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

M Hatzinger, and J M Reul, and R Landgraf, and F Holsboer, and I Neumann
July 1984, British journal of anaesthesia,
M Hatzinger, and J M Reul, and R Landgraf, and F Holsboer, and I Neumann
April 1976, The Journal of pharmacy and pharmacology,
M Hatzinger, and J M Reul, and R Landgraf, and F Holsboer, and I Neumann
January 2001, Neurobiology of aging,
M Hatzinger, and J M Reul, and R Landgraf, and F Holsboer, and I Neumann
January 1996, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association,
M Hatzinger, and J M Reul, and R Landgraf, and F Holsboer, and I Neumann
April 2002, Sleep medicine reviews,
M Hatzinger, and J M Reul, and R Landgraf, and F Holsboer, and I Neumann
January 1973, Acta haematologica Polonica,
M Hatzinger, and J M Reul, and R Landgraf, and F Holsboer, and I Neumann
January 1987, Advances in biochemical psychopharmacology,
M Hatzinger, and J M Reul, and R Landgraf, and F Holsboer, and I Neumann
June 1986, Biulleten' eksperimental'noi biologii i meditsiny,
M Hatzinger, and J M Reul, and R Landgraf, and F Holsboer, and I Neumann
February 1985, Archives of general psychiatry,
Copied contents to your clipboard!